Liver transplantation in highest acuity recipients: Identifying factors to avoid futility

Annals of Surgery

Volumn 259, Issue 6, 2014, Pages 1186-1194

  Petrowsky, Henrik ^a   Rana, Abbas ^a   Kaldas, Fady M ^a   Sharma, Anuj ^a   Hong, Johnny C ^a   Agopian, Vatche G ^a   Durazo, Francisco ^a   Honda, Henry ^a   Gornbein, Jeffrey ^a   Wu, Victor ^b   Farmer, Douglas G ^a   Hiatt, Jonathan R ^a   Busuttil, Ronald W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

Extreme recipient; Futiliy; High acuity; Liver transplantation; Outcome

Indexed keywords

ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; END STAGE LIVER DISEASE; FAILURE FREE SURVIVAL; FEMALE; HEPATITIS C; HIGH RISK POPULATION; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; MULTIPLE ORGAN FAILURE; OPERATION DURATION; PATIENT ACUITY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; TREATMENT OUTCOME;

CALIFORNIA; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HOSPITAL MORTALITY; HUMANS; INCIDENCE; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MEDICAL FUTILITY; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84900836924     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000265     Document Type: Article

References (50)

1. Wertheim JA, Petrowsky H, Saab S, et al. Major challenges limiting liver transplantation in the United States. Am J Transplant. 2011;11:1773-1784
2. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464-470
3. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91-96
4. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant. 2005;5:307-313
5. Schaubel DE, Guidinger MK, Biggins SW, et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant. 2009;9:970-981
6. Thuluvath PJ, GuidingerMK, Fung JJ, et al. Liver transplantation in the United States, 1999-2008. Am J Transplant. 2010;10:1003-1019
7. Raval Z, Harinstein ME, Skaro AI, et al. Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol. 2011;58:223-231
8. Xia VW, Taniguchi M, Steadman RH. The changing face of patients presenting for liver transplantation. Curr Opin Organ Transplant. 2008;13:280-284
9. Yeh H, Smoot E, Schoenfeld DA, et al. Geographic inequity in access to livers for transplantation. Transplantation. 2011;91:479-486
10. Ammori JB, Pelletier SJ, Lynch R, et al. Incremental costs of post-liver transplantation complications. J Am Coll Surg. 2008;206:89-95
11. Buchanan P, Dzebisashvili N, Lentine KL, et al. Liver transplantation cost in the model for end-stage liver disease era: Looking beyond the transplant admission. Liver Transpl. 2009;15:1270-1277
12. Foxton MR, Al-Freah MA, Portal AJ, et al. Increased model for end-stage liver disease score at the time of liver transplant results in prolonged hospitalization and overall intensive care unit costs. Liver Transpl. 2010;16:668-677
13. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: The concept of a donor risk index. Am J Transplant. 2006;6:783-790
14. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-553
15. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428
16. Charlson ME, Pompei P,AlesKL, et al.Anewmethod of classifying prognostic comorbidity in longitudinal studies: Development and validation. JChronicDis. 1987;40:373-383
17. Busuttil RW, Lipshutz GS, Kupiec-Weglinski JW, et al. rPSGL-Ig for improvement of early liver allograft function: A double-blind, placebo-controlled, single-center phase II study. Am J Transplant. 2011;11:786-797
18. Ghobrial RM, Farmer DG, Baquerizo A, et al. Orthotopic liver transplantation for hepatitis C: Outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg. 1999;229:824-831; discussion 831-823
19. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-213
20. Neuberger J, Gimson A, Davies M, et al. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut. 2008;57:252-257
21. Watt KD, Coss E, Pedersen RA, et al. Pretransplant serum troponin levels are highly predictive of patient and graft survival following liver transplantation. Liver Transpl. 2010;16:990-998
22. Volk ML, Hernandez JC, Lok AS, et al. Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl. 2007;13:1515-1520
23. Yong CM, Sharma M, Ochoa V, et al. Multivessel coronary artery disease predicts mortality, length of stay, and pressor requirements after liver transplantation. Liver Transpl. 2010;16:1242-1248
24. De Groot V, Beckerman H, Lankhorst GJ, et al. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol. 2003;56: 221-229
25. Grosso G, di Francesco F, Vizzini G, et al. The Charlson comorbidity index as a predictor of outcomes in liver transplantation: Single-center experience. Transplant Proc. 2012;44:1298-1302
26. Chavez-Tapia NC, Torre-Delgadillo A, Tellez-Avila FI, et al. The molecular basis of susceptibility to infection in liver cirrhosis. Curr Med Chem. 2007;14:2954-2958
27. Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor for sepsis and death: Analysis of the National Hospital Discharge Survey. Chest. 2003;124:1016-1020
28. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28:26-42
29. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005;365:63-78
30. Gaskari SA, Honar H, Lee SS. Therapy insight: Cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol. 2006;3:329-337
31. Newby DE, Hayes PC. Hyperdynamic circulation in liver cirrhosis: Not peripheral vasodilatation but 'splanchnic steal'. QJM. 2002;95:827-830
32. Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: Report on the 7th meeting of the International Ascites Club. Gut. 2005;54:718-725
33. Sun HY, Cacciarelli TV, Singh N. Impact of pretransplant infections on clinical outcomes of liver transplant recipients. Liver Transpl. 2010;16:222-228
34. Van Thiel DH, Hassanein T, Gurakar A, et al. Liver transplantation after an acute episode of spontaneous bacterial peritonitis. Hepatogastroenterology. 1996;43:1584-1588
35. Rana A, HardyMA, HalazunKJ, et al. Survival outcomes following liver transplantation (SOFT) score: A novel method to predict patient survival following liver transplantation. Am J Transplant. 2008;8:2537-2546
36. Dutkowski P, Oberkofler CE, Slankamenac K, et al. Are there better guidelines for allocation in liver transplantation?. A novel score targeting justice and utility in the model for end-stage liver disease era. Ann Surg. 2011;254:745-753; discussion 753
37. Gomez EV, Bertot LC, Oramas BG, et al. Application of a biochemical and clinical model to predict individual survival in patients with end-stage liver disease. World J Gastroenterol. 2009;15:2768-2777
38. Berg CL, Steffick DE, Edwards EB, et al. Liver and intestine transplantation in the United States 1998-2007. Am J Transplant. 2009;9: 907-931
39. Dutkowski P, De Rougemont O, Mullhaupt B, et al. Current and future trends in liver transplantation in Europe. Gastroenterology. 2010;138:802-809; e801-e804
40. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889-896
41. O'Leary JG, Randall H, Onaca N, et al. Post-liver transplant survival in hepatitis C patients is improving over time. Liver Transpl. 2009;15:360-368
42. Parekh J, Corley DA, Feng S. Diabetes, hypertension and hyperlipidemia: Prevalence over time and impact on long-Term survival after liver transplantation. Am J Transplant. 2012;12:2181-2187
43. Watt KD, Pedersen RA, Kremers WK, et al. Evolution of causes and risk factors for mortality post-liver transplant: Results of the NIDDK long-Term follow-up study. Am J Transplant. 2010;10:1420-1427
44. Laish I, Braun M, Mor E, et al. Metabolic syndrome in liver transplant recipients: Prevalence, risk factors, and association with cardiovascular events. Liver Transpl. 2011;17:15-22
45. Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: A review and guide to management. J Hepatol. 2010;53:199-206
46. Hanouneh IA, Feldstein AE, McCullough AJ, et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl. 2008;14:1287-1293
47. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194
48. Johnston SD, Morris JK, Cramb R, et al. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation. 2002;73:901-906
49. Marsh JW, Gray E, Ness R, et al. Complications of right lobe living donor liver transplantation. J Hepatol. 2009;51:715-724
50. Yao FY. Liver transplantation for hepatocellular carcinoma: Beyond the Milan criteria. Am J Transplant. 2008;8:1982-1989.